Factors impacting trial participation in people with motor neuron disease.
Amyotrophic lateral sclerosis
Clinical trials
Motor neuron disease
Recruitment
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
03 Oct 2023
03 Oct 2023
Historique:
received:
21
07
2023
accepted:
15
09
2023
revised:
12
09
2023
medline:
3
10
2023
pubmed:
3
10
2023
entrez:
3
10
2023
Statut:
aheadofprint
Résumé
Motor neuron disease (MND) is a rapidly progressive neurodegenerative disorder with limited treatment options. Historically, neurological trials have been plagued by suboptimal recruitment and high rates of attrition. The Motor Neuron Disease-Systematic Multi-Arm Randomised Adaptive Trial (MND-SMART) seeks to identify effective disease modifying drugs. This study investigates person-specific factors affecting recruitment and retention. Improved understanding of these factors may improve trial protocol design, optimise recruitment and retention. Participants with MND completed questionnaires and this was supplemented with clinical data. 12 months after completing the questionnaires we used MND-SMART recruitment data to establish if members of our cohort engaged with the trial. 120 people with MND completed questionnaires for this study. Mean age at participation was 66 (SD = 9), 14% (n = 17) were categorised as long survivors, with 68% (n = 81) of participants male and 60% (n = 73) had the ALS sub-type. Of the 120 study participants, 50% (n = 60) were randomised into MND-SMART and 78% (n = 94) expressed interest an in participating. After the 1-year follow-up period 65% (n = 39) of the 60 randomised participants remained in MND-SMART. Older age was significantly associated with reduced likelihood of participation (OR = 0.92, 95% CI = 0.88-0.96, p = 0.000488). The findings show that people with MND are highly motivated to engage in research, but older individuals remain significantly less likely to participate. We recommend the inclusion of studies to explore characteristics of prospective and current participants alongside trials.
Identifiants
pubmed: 37787812
doi: 10.1007/s00415-023-12010-8
pii: 10.1007/s00415-023-12010-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Chiò A et al (2009) Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 72(8):725–731
doi: 10.1212/01.wnl.0000343008.26874.d1
pubmed: 19237701
Xu L et al (2020) Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol 267(4):944–953
doi: 10.1007/s00415-019-09652-y
pubmed: 31797084
Wong C et al (2021) Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Commun 3(4):fcab242
doi: 10.1093/braincomms/fcab242
pubmed: 34901853
pmcid: 8659356
Mitsumoto H, Brooks BR, Silani V (2014) Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 13(11):1127–1138
doi: 10.1016/S1474-4422(14)70129-2
pubmed: 25316019
Bowser R, Turner MR, Shefner J (2011) Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol 7(11):631–638
doi: 10.1038/nrneurol.2011.151
pubmed: 21989244
Abe K et al (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505–512
doi: 10.1016/S1474-4422(17)30115-1
Paganoni S et al (2020) Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 383(10):919–930
doi: 10.1056/NEJMoa1916945
pubmed: 32877582
pmcid: 9134321
Dumville JC, Torgerson DJ, Hewitt CE (2006) Reporting attrition in randomised controlled trials. BMJ 332(7547):969–971
doi: 10.1136/bmj.332.7547.969
pubmed: 16627519
pmcid: 1444839
Min JH et al (2012) Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. J Korean Med Sci 27(2):200–206
doi: 10.3346/jkms.2012.27.2.200
pubmed: 22323869
pmcid: 3271295
Beghi E et al (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener 14(5–6):397–405
doi: 10.3109/21678421.2013.764568
pubmed: 23421600
Polit D, Hungler B (2001) Essentials of nursing research: principles and methods. Lippincott Williams & Williams, Philadelphia
Gul RB, Ali PA (2010) Clinical trials: the challenge of recruitment and retention of participants. J Clin Nurs 19(1–2):227–233
doi: 10.1111/j.1365-2702.2009.03041.x
pubmed: 20500260
Gross D, Fogg L (2001) Clinical trials in the 21st century: the case for participant-centered research. Res Nurs Health 24(6):530–539
doi: 10.1002/nur.10010
pubmed: 11746081
Beswick E et al (2021) Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol. BMJ Open 11(3):e044996
doi: 10.1136/bmjopen-2020-044996
pubmed: 33757953
pmcid: 7993162
Leighton D et al (2019) Clinical audit research and evaluation of motor neuron disease (CARE-MND): a national electronic platform for prospective, longitudinal monitoring of MND in Scotland. Amyotroph Lateral Scler Frontotemporal Degener 20(3–4):242–250
doi: 10.1080/21678421.2019.1582673
pubmed: 30889975
Niven E et al (2015) Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener 16(3–4):172–179
doi: 10.3109/21678421.2015.1030430
pubmed: 25967542
Leighton DJ et al (2019) Changing epidemiology of motor neurone disease in Scotland. J Neurol 266(4):817–825
doi: 10.1007/s00415-019-09190-7
pubmed: 30805795
Atassi N et al (2013) Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology 81(15):1350–1355
doi: 10.1212/WNL.0b013e3182a823e0
pubmed: 24005339
pmcid: 3806927
Bedlack RS et al (2008) Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler 9(5):257–265
doi: 10.1080/17482960802195913
pubmed: 18608092
Ford JG et al (2008) Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112(2):228–242
doi: 10.1002/cncr.23157
pubmed: 18008363
Syková E et al (2017) Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase I/IIa clinical trial. Cell Transpl 26(4):647–658
doi: 10.3727/096368916X693716
Radakovic R et al (2016) Multidimensional apathy in ALS: validation of the Dimensional Apathy Scale. J Neurol Neurosurg Psychiatry 87(6):663–669
doi: 10.1136/jnnp-2015-310772
pubmed: 26203157
Cummings J et al (2015) Apathy in neurodegenerative diseases: recommendations on the design of clinical trials. J Geriatr Psychiatry Neurol 28(3):159–173
doi: 10.1177/0891988715573534
pubmed: 25809634
Chio A et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10(5–6):310–323
doi: 10.3109/17482960802566824
pubmed: 19922118
pmcid: 3515205
Beswick E et al (2020) A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis. J Neurol. https://doi.org/10.3109/17482960802566824
doi: 10.3109/17482960802566824
pubmed: 32910255
pmcid: 8563523
Van Den Berg LH et al (2019) Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 92(14):e1610–e1623
doi: 10.1212/WNL.0000000000007242
pubmed: 30850440
pmcid: 6448453